Incyte Plummets 13% As Skin Disease Drug Looks 'Viable, But Not Competitive'
Incyte's skin disease treatment looks "viable, but not competitive with biologics," an analyst said Monday as Incyte stock crashed. The post Incyte Plummets 13% As Skin Disease Drug Looks 'Viable, But Not Competitive' appeared first on Investor's Business Daily.
Incyte's skin disease treatment looks "viable, but not competitive with biologics," an analyst said Monday as Incyte stock crashed.
The post Incyte Plummets 13% As Skin Disease Drug Looks 'Viable, But Not Competitive' appeared first on Investor's Business Daily.
iShook Opinion
"iShook Opinion" by Beni E Rachmanov, CEO & Founder of iShook. Explore captivating perspectives on entertainment, lifestyle, and sports at ishookdaily.com. Your go-to for engaging insights.
